Abstracts tagged "clinical trials and ulcers"

Abstract Number: 1791 • 2018 ACR/ARHP Annual Meeting
Efficacy of Apremilast for Oral Ulcers Associated with Active Behçet’s Syndrome in a Phase III Study: A Prespecified Analysis By Baseline Patient Demographics and Disease Characteristics
Gulen Hatemi¹, Alfred Mahr², Mitsuhiro Takeno³, Do-Young Kim⁴, Melike Melikoglu¹, Sue Cheng⁵, Shannon McCue⁵, Maria Paris⁵, Mindy Chen⁵ and Yusuf Yazici⁶, ¹Istanbul University Cerrahpasa Medical School, Istanbul, Turkey, ²Hospital Saint-Louis, University Paris Diderot, Paris, France, ³Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ⁴Yonsei University College of Medicine and Severance Hospital, Seoul, Korea, Republic of (South), ⁵Celgene Corporation, Summit, NJ, ⁶New York University School of Medicine, New York, NY
Background/Purpose: Behçet’s syndrome is a chronic, multi-system inflammatory disorder characterized by recurrent oral ulcers (OU) that can be disabling and negatively affect quality of life.…
Abstract Number: 2789 • 2018 ACR/ARHP Annual Meeting
Efficacy of Apremilast for Oral Ulcers Associated with Active Behçet’s Syndrome over 28 Weeks: Results from a Phase III Study
Gulen Hatemi¹, Alfred Mahr², Yoshiaki Ishigatsubo³, Yeong Wook Song⁴, Melike Melikoglu⁵, Sue Cheng⁶, Shannon McCue⁶, Maria Paris⁶, Mindy Chen⁶ and Yusuf Yazici⁷, ¹Rheumatology, Istanbul University, Cerrahpasa Medical School, Istanbul, Turkey, ²Hospital Saint-Louis, University Paris Diderot, Paris, France, ³Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁴Rheumatology, Seoul National University Hospital, Seoul, Korea, Republic of (South), ⁵Istanbul University Cerrahpasa Medical School, Istanbul, Turkey, ⁶Celgene Corporation, Summit, NJ, ⁷New York University School of Medicine, New York, NY
Background/Purpose: Behçet’s syndrome is a chronic, relapsing, multi-system inflammatory disorder characterized by recurrent oral ulcers (OU), which can be disabling and substantially impact quality of…
Abstract Number: 2841 • 2018 ACR/ARHP Annual Meeting
Apremilast for Behçet’s Syndrome: Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study in a Japanese Subgroup
Mitsuhiro Takeno¹, Yoshiya Tanaka², Hajime Kono³, Shouji Sugii⁴, Mitsumasa Kishimoto⁵, Sue Cheng⁶, Shannon McCue⁶, Maria Paris⁶ and Hiroaki Dobashi⁷, ¹Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ⁴Department of Rheumatology, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, ⁵Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ⁶Celgene Corporation, Summit, NJ, ⁷Internal Medicine Division of Hematology, Rheumatology, and Respiratory Medicine, Kagawa University, Kagawa, Japan
Background/Purpose: Apremilast, an oral phosphodiesterase 4 inhibitor, demonstrated efficacy in a global, phase III, multicenter, randomized, double-blind, placebo-controlled study in patients with Behçet’s syndrome and…
Abstract Number: 2756 • 2014 ACR/ARHP Annual Meeting
Treatment of Mucocutaneous Manifestations in Behçet’s Disease with Anakinra: A Pilot Open-Label Study
Peter C. Grayson¹, Yusuf Yazici², Elaine Novakovich³, Elizabeth Joyal⁴, Raphaela T. Goldbach-Mansky⁴ and Cailin H. Sibley^3,5, ¹NIAMS Systemic Autoimmunity Branch, National Institutes of Health, Bethesda, MD, ²Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³National Institutes of Health Clinical Center, Bethesda, MD, ⁴NIAMS, National Institutes of Health Clinical Center, Bethesda, MD, ⁵Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR
Background/Purpose: IL-1 blocking therapy shows promise in the treatment of Behçet’s eye disease, but its effect on mucocutaneous manifestations is unknown. Methods: 6 patients with…